Regulus Therapeutics is a biotechnology business based in the US. Regulus Therapeutics shares (RGLS) are listed on the NASDAQ and all prices are listed in US Dollars. Regulus Therapeutics employs 28 staff and has a trailing 12-month revenue of around $5 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.76 |
|---|---|
| 52-week range | $1.08 - $3.00 |
| 50-day moving average | $2.06 |
| 200-day moving average | $1.76 |
| Wall St. target price | $11.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.45 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.76 from 2024-07-25
| 1 week (2024-07-19) | 6.67% |
|---|---|
| 1 month (2024-06-27) | -13.09% |
| 3 months (2024-04-26) | -27.27% |
| 6 months (2024-01-26) | 39.68% |
| 1 year (2023-07-27) | 32.33% |
|---|---|
| 2 years (2022-07-27) | 7.32% |
| 3 years (2021-07-27) | 151.43% |
| 5 years (2019-07-26) | 153.24% |
| Revenue TTM | $5 million |
|---|---|
| Gross profit TTM | $-18,410,000 |
| Return on assets TTM | -26.93% |
| Return on equity TTM | -46.75% |
| Profit margin | 0% |
| Book value | $1.64 |
| Market Capitalization | $108 million |
TTM: trailing 12 months
We're not expecting Regulus Therapeutics to pay a dividend over the next 12 months.
Regulus Therapeutics's shares were split on a 1:10 basis on 28 June 2022. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Regulus Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Regulus Therapeutics shares which in turn could have impacted Regulus Therapeutics's share price.
Over the last 12 months, Regulus Therapeutics's shares have ranged in value from as little as $1.08 up to $3. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Regulus Therapeutics's is 1.621. This would suggest that Regulus Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Regulus Therapeutics Inc. , a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. .
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.